Introduction {#Sec1}
============

Uterine sarcomas are a heterogeneous group of rare tumors that constitute up to 8 % of cancers of the uterine corpus and 1 % of all tumors of the female genital tract \[[@CR1], [@CR2]\]. Uterine sarcomas are classified as mesenchymal tumors (endometrial sarcomas and leiomyosarcomas) and mixed epithelial--mesenchymal tumors (including adenosarcomas and carcinosarcomas) \[[@CR3]\]. Carcinosarcomas were reclassified as a dedifferentiated or metaplastic form of endometrial carcinoma but are still included in the 2003 World Health Organization (WHO) classification \[[@CR3], [@CR4]\]. Uterine sarcomas are among the most lethal uterine malignancies with worse prognosis than other gynecologic malignancies; 5-year survival rate is below 50 % for stage I and less than 30 % for the remaining stages \[[@CR2]\]. This group of tumors must be considered in a differential diagnosis of patients with abnormal uterine bleeding. Preoperative diagnosis of uterine sarcomas, including imaging-based diagnosis, is extremely difficult because there are no unambigous pathognomonic features of this group of tumors. Since uterine sarcomas are rarely diagnosed preoperatively, the initial treatment is often based on an inappropriate diagnosis.

microRNAs (miRNAs, miRs) are approximately 22-nucleotide long, non-coding RNAs that regulate the translation of the coding mRNAs. These molecules are generally considered to be negative regulators of gene expression \[[@CR5]\], yet they may also function as inducers of translation \[[@CR6]\]. miRNAs are involved in a variety of both normal and pathological biological processes. They are key players in the regulation of carcinogenesis where they may play a role of either tumor inducers (so-called oncomirs) or supressors \[[@CR7]\]. Accumulating data on miRNAs' expression in different tumor types points to miRNAs as putative diagnostic, prognostic, and predictive markers.

This study aimed at identification of miRNA expression patterns in uterine sarcomas and mixed epithelial--mesenchymal uterine tumors.

Materials and methods {#Sec2}
=====================

Ten patients treated for endometrial sarcoma, 8 for leiomyosarcoma, and 11 treated for mixed epithelial--mesenchymal tumors at the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology in Warsaw, between February 2009 and December 2010, were enrolled. The selected patients' characteristics are presented in Table [1](#Tab1){ref-type="table"}. The study was approved by the Independent Ethics Committee of the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology in Warsaw and all patients gave their informed consent. Tissue specimens were divided into two parts: one part was examined histologically and the other was frozen in liquid nitrogen and stored at −70 °C until RNA isolation. In addition to 29 tumor tissue samples, 12 samples of normal uterine tissue were also collected from patients enrolled in the study.Table 1Individual patient dataPatientAge (years)Tumor typeTumor histology/histological gradeSamples analyzedMesenchymal tumorsEndometrial sarcomas676.7RecurrentEndometrial stromal sarcoma, low gradeT1360.1RecurrentUndifferentiated endometrial sarcomaT1643.3PrimaryUndifferentiated endometrial sarcomaT1774.8PrimaryUndifferentiated endometrial sarcomaT, C3151.0PrimaryEndometrial stromal sarcoma, low gradeT, C3664.6PrimaryUndifferentiated endometrial sarcomaT, C3844.8PrimaryEndometrial stromal sarcoma, low gradeT, C5278.1PrimaryUndifferentiated endometrial sarcomaT6253.4PrimaryUndifferentiated endometrial sarcomaT, C6468.9PrimaryUndifferentiated endometrial sarcomaTSmooth muscle tumors252.6RecurrentLeiomyosarcoma/G3T, C1256.3PrimaryLeiomyosarcoma/G3T, C2363.2RecurrentLeiomyosarcoma/G2T2645.8RecurrentLeiomyosarcoma/G3T2851.5RecurrentLeiomyosarcoma/G2T3557.5RecurrentLeiomyosarcoma/G2T6340.5RecurrentLeiomyosarcoma/G3T9059.1RecurrentLeiomyosarcoma/G2TMixed epithelial and mesenchymal tumors375.5RecurrentCarcinosarcoma heterologous^a^T1161.4PrimaryCarcinosarcoma homologous^b^T, C1423.2PrimaryAdenosarcoma homologousT, C1866.4PrimaryCarcinosarcoma heterologousT2466.6PrimaryCarcinosarcoma heterologousT, C2561.0RecurrentCarcinosarcoma homologousT3064.3PrimaryCarcinosarcoma heterologousT, C6655.1PrimaryCarcinosarcoma homologousT, C6759.7PrimaryAdenosarcoma homologousT7155.5RecurrentAdenosarcoma homologousT8653.8RecurrentAdenosarcoma homologousTAbbreviations: *T* tumor sample, *C* control, i.e., a sample of normal uterine tissue obtained from the same patient^a^Heterologous tumor---representing malignant counterparts that normally do not occur in the uterus^b^Homologous tumor---representing malignant counterparts of tissues indigenous to the uterus

Human uterine sarcoma cell lines MES-SA (CRL-1976, derived from a poorly differentiated uterine sarcoma) and SK-UT-1 (derived from mixed mesodermal tumor) purchased from the American Type Tissue Collection, were cultured in the McCoy's 5A and Dulbecco's modified Eagle's medium, respectively, supplemented with 10 % of FCS (Gibco) and gentamycin (Sigma). Cells were seeded at 50 × 10^3^, in 75-cm^2^ bottles and passaged every 4--5 days by trypsinisation. 5 × 10^6^ cells were collected, washed three times in PBS at 4 °C, snap-frozen and stored at --70 °C until RNA isolation.

Total RNA was isolated from approximately 50 mg of pulverized (with the Microdismembrator II, B Braun Biotech International) tissues as well as from harvested MES-SA and SK-UT-1 cell lines using miRNeasy Mini Kit with on-column DNase digestion (Qiagen), according to the manufacturer's protocol. RNA quantity was assessed using the NanoDrop 2000 Spectrophotometer (ThermoScientific), while its quality was visually assessed following gel electrophoresis using FlashGel System (Lonza). RNA was extracted from 41 tissue samples (29 tumors and 12 control samples, i.e., fragments of normal uterine tissues). Reverse transcription was performed on 1 μg total RNA with the RT^2^ miRNA First Strand Kit (Qiagen) and used for Human Cancer microRNA PCR Arrays (MAH-102 from SABiosciences, miRNA list available at <http://www.sabiosciences.com/mirna_pcr_product/HTML/MAH-102A.html>).

Quantitative real-time PCR (qPCR) analysis was performed with the RT^2^ Real-Time PCR Master Mix (SABiosciences) in the 7500 Fast Real-Time PCR System (Applied Biosystems) following the manufacturer's protocol (SABiosciences). The collected data were analyzed using threshold-cycle (Ct) values for the miRNAs with the SDS 2.1 software (Applied Biosystems). The normalized miR expression values in uterine sarcomas and mixed epithelial--mesenchymal uterine tumors as well in the cell lines were determined with DataAssist software (Applied Biosystems).

The Wilcoxon signed-rank test was used to test significance of difference in miRs' expression between the tumor tissues and control samples. The statistical analysis was carried out using the R software (version 2.14.1, <http://www.R-project.org>). *P* values were corrected for multiple hypotheses using Benjamini--Hochberg algorithm. The differences were considered statistically significant at *P* \< 0.05. Expression levels for the selected miRs were graphed using R software.

Results {#Sec3}
=======

Four potential reference genes for RT-qPCR application, namely SNORD44, SNORD47, SNORD48, and RNU6-2, were evaluated for normalization in 41 tissue samples (29 tumors and 12 fragments of normal uterine tissues) as well as in the two human sarcoma cell lines: MES-SA and SK-UT-1. Based on the expression stability values obtained in the data analysis using the geNorm™ algorithm (integrated into DataAssist software), SNORD47 and RNU6-2 were chosen as reference genes.

miRNAs isolated from 41 fresh-frozen specimens obtained from patients with uterine sarcomas and mixed epithelial--mesenchymal uterine tumors were tested for the expression of 88 types of miRNA known to be involved in carcinogenesis. Expression levels were analyzed using DataAssist software and values were normalized to SNORD47 and RNU6-2.

Fold changes in the median expression values of miRs that were significantly differentially expressed between tumor (*n* = 29) and control (*n* = 12) samples are presented in Table [2](#Tab2){ref-type="table"}. The fold changes in the miRs' expression values in the MES-SA and SKUT-1 cell lines related to the control uterine tissue samples, compared to the results obtained in clinical samples, are provided in Electronic supplementary material (ESM) Supplementary Fig. [1](#MOESM2){ref-type="media"}.Table 2Fold changes (FC) in the median expression values of the significantly (*P* \< 0.05) differentially expressed miRs in all the analyzed tumors (*n* = 29) compared to control (*n* = 12) samples, *P* value for differential expression between tumors and controls from Wilcoxon signed rank test adjusted for multiple hypotheses testingmiRFC*P* valuemiR-10b0.040.029miR-10.050.022miR-23b0.070.009miR-125b0.080.022miR-1430.090.019let-7c0.120.000let-7b0.150.002miR-1500.180.029miR-27b0.210.012let-7a0.210.004miR-193a-5p0.250.023let-7e0.250.006let-7f0.290.015let-7d0.350.011miR-1260.370.029miR-2140.500.006

Subsequently, the expression data were analyzed within the three groups of uterine tumors---endometrial sarcomas (*n* = 10), leiomyosarcomas (*n* = 8), and mixed epithelial--mesenchymal tumors (*n* = 11)---compared to all the control (*n* = 12) samples. Four miR genes, namely *miR-23b*, *miR-1*, *let-7f*, and *let-7c*, were found to be down-regulated in endometrial sarcomas when compared to the control samples (see Fig. [1](#Fig1){ref-type="fig"}). The expression levels of 12 miRs, *miR-1*, *let-7c*, *miR-133b*, *let-7b*, *miR-143*, *let-7a*, *let-7d*, *let-7e*, *let-7g*, *miR-222*, *let-7i*, and *miR-214*, which were down-regulated in mixed epithelial--mesenchymal tumors are presented in Fig. [2](#Fig2){ref-type="fig"}. The expression of the above-mentioned miRs' presented in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} significantly differed (*P* \< 0.05) between the tumor and control samples. No statistically significant changes in miRNA expression levels were found between leiomyosarcoma tumors and controls.Fig. 1Differential expression of *miR-23b*, *miR-1*, *let-7f*, and *let-7c* in the normal uterine fragments (controls, *C*) and in endometrial sarcoma tumors (*T*). *Lines* indicate median valuesFig. 2Differential expression of *miR-1*, *let-7c*, *miR-133b*, *let-7b*, *miR-143*, *let-7a*, *let-7d*, *let-7e*, *let-7g*, *miR-222*, *let-7i*, and *miR-214* in the normal uterine fragments (controls, *C*) and in the mixed epithelial--mesenchymal uterine tumors (*T*). *Lines* indicate median values

The fold change values in the median expression of all the analyzed miRs between tumor and control samples, stratified by the disease type, are presented in ESM Supplementary Table [1](#MOESM1){ref-type="media"}.

Discussion {#Sec4}
==========

Uterine sarcomas present a significant therapeutic problem. Clinical data demonstrate the aggressive behavior of these tumors, with a high recurrence rate, and despite development of new adjuvant treatments patient outcomes have not improved. The benefits of chemotherapy are limited, and radiotherapy can result in a lower rate of local recurrence but still has no effect on patients' overall survival \[[@CR8]\]. Implementation of targeted therapy and individualized treatment of uterine sarcoma patients appears necessary \[[@CR4]\]. Different course of this disease is associated not only with the histopathological variety of the tumors, as even patients with the same diagnosis may present different disease course. However, while individualized treatment should be based on preoperative diagnosis, the differential diagnosis of uterine tumors frequently causes problems \[[@CR9]\].

Our goal was to identify alterations in miRNA expression in pure mesenchymal tumors and mixed epithelial--mesenchymal tumors of the uterus. The vast majority of 88 miR molecules analyzed here was down-regulated in the analyzed tumors when compared to normal uterine fragments. Pan et al. \[[@CR10]\] observed a significantly lower number of miRNAs expressed in leiomyomas compared with normal myometrium, and a further reduction of miRNA expression in T-LSMC, a transformed culture of leiomyoma and SKLM-1, a leiomyosarcoma cell line, provided grounds to the authors' hypothesis on the biological significance of these miRNAs and their target genes in the pathogenesis of leiomyosarcoma. Our observations were consistent with this hypothesis and extended it to uterine leiomyosarcomas as well as to endometrial sarcomas and mixed epithelial--mesenchymal tumors.

To our knowledge, miRNA signatures of uterine pure mesenchymal and mixed epithelial--mesenchymal tumors of different subtypes have not been previously studied. In our study, four miRs, i.e., *miR-23b*, *miR-1*, *let-7f*, and *let-7c*, were found to be down-regulated in endometrial sarcomas vs. control samples.

In the only other study to have examined miR expression in mixed uterine tumors, Ratner et al. \[[@CR11]\] found miRNA signatures that discriminated carcinosarcomas from uterine carcinomas. In carcinosarcomas, they revealed up-regulated *miR-19a* and *miR-19b*---compared to endometrioid tumors, *miR-182*---compared to papillary serous carcinomas, *miR-301*, *miR-20b*, and *miR-487b*---jointly compared to endometrioid and papillary serous tumors. The down-regulated miRs in carcinosarcomas included *miR-133a*---as compared to endometrioid tumors, *miR-22*---as compared to papillary serous carcinomas, and *miR-518b*---as compared to endometrioid and papillary serous tumors, jointly. In accordance, we found mixed tumors to over-express *miR-19a*, *miR-301a*, and *miR-20b*; however, this has not reached statistical significance. The remaining miR molecules (*miR-19b*, *miR-182*, *miR-487b*, *miR-133a*, *miR-22*, and *miR-518b*) warrant further investigation. As we showed here, mixed epithelial--mesenchymal tumors compared to the normal uterine fragments, expressed decreased levels of 12 miRs (*miR-1*, *let-7c*, *miR-133b*, *let-7b*, *miR-143*, *let-7a*, *let-7d*, *let-7e*, *let-7g*, *miR-222*, *let-7i*, and *miR-214*).

Pan et al. \[[@CR10]\] documented *miR-20a*, *miR-21*, and *miR-206* to be up-regulated and *miR-142-5p* to be down-regulated in leiomyomas obtained from Caucasians as normalized to normal *myometrium*. The results obtained by Wang et al. \[[@CR12]\] indicate that uterine leiomyomas, when compared to the matched myometrium, have a homogenous and specific miRNA signature, involving significantly over-expressed *let-7* family, *miR-21*, *miR-23b*, and *miR-27a* as well as down-regulated *miR-29b*, *miR-32*, *miR-144*, and *miR-212*. Table [3](#Tab3){ref-type="table"} summarizes a comparison between our results and those of Pan et al. \[[@CR10]\] and Wang et al. \[[@CR12]\] on leiomyomas, and reveals that a decrease in *miR-29b* and *miR-212* expression is commonly shared by leiomyomas, uterine sarcomas, and mixed epithelial--mesenchymal tumors. Studies in a mouse model of rhabdomyosarcoma have shown that reconstitution of *miR-29b*/*c* \[[@CR13]\] and *miR-206* \[[@CR14]\] inhibits tumor growth and stimulates muscle differentiation, suggesting their role of a tumor suppressor. Correspondingly, *miR-29b* was down-regulated in all tumors examined in our study. However, an unexpected trend (though insignificant) towards *miR-206* up-regulation was observed in endometrial sarcomas and mixed epithelial--mesenchymal tumors. Similarly Pan et al. \[[@CR15]\] demonstrated *miR-206* to be up-regulated in ectopic endometrium compared to the paired eutopic endometrium of women with endometriosis. In a recent study, Jin et al. \[[@CR16]\] demonstrated that angiotensin II (Ang II) increased the expression of miR-132 and miR-212 cluster (miR-132/212) in rat vascular smooth muscle cells (RVSMC) in vitro, and in the aortas of Ang II-infused mice in vivo. These authors observed a positive feedback loop mechanism between cyclic AMP-response element binding protein activation and miR-132 expression and revealed that a subset of genes down-regulated by Ang II was a predicted target of miR-132. A key role of miR-132/212 in Ang II-induced monocyte chemoattractant protein-1 (*MCP-1*) gene expression in RVSMC was discovered. In RVSMC, Jin et al. \[[@CR16]\] proved that phosphatase and tensin homolog (PTEN) is a target of miR-132, and that the induction of *MCP-1* occurs via PTEN repression. Mutational inactivation of *PTEN* is not a common event in uterine sarcomas \[[@CR17], [@CR18]\], though in carcinosarcomas it may play a tumorogenic role \[[@CR19]\]. Our data do not support the repression of *PTEN* in uterine sarcomas and mixed epithelial--mesenchymal tumors via miR-132/212, as both members of this cluster were down-regulated in all the tumors analyzed in our study.Table 3Comparison of our results with those obtained by Pan et al. \[[@CR10]\] and Wang et al. \[[@CR12]\] for leiomyomasmiRLeiomyomasEndometrial sarcomasLeiomyosarcomasMixed epithelial--mesenchymal tumors*miR-20a*↑ \[[@CR10]\]↑↓↑*miR-21*^a^↑ \[[@CR10], [@CR12]\]↓↓↓*miR-206*↑ \[[@CR10]\]↑↓↑*miR-142-5p*↓ \[[@CR10]\]↑↓↑*let-7* family^a^↑ \[[@CR12]\]↓↓↓*miR-23b*^a^↑ \[[@CR12]\]↓↓↓*miR-27a*^a^↑ \[[@CR12]\]↓↓↓*miR-29b*↓ \[[@CR12]\]↓↓↓*miR-32*^a^↓ \[[@CR12]\]↑↑↑*miR-144*^a^↓ \[[@CR12]\]------*miR-212*↓ \[[@CR12]\]↓↓↓"↑" -- increased, "↓" -- decreased, and "--" unchanged expression levels in tumors vs control samples^a^miRs that are differentially expressed between malignant and benign lesions

Importantly, the distinct patterns of expression of *miR-21*, *let-7* family, *miR-23b*, and *miR-27a* between our samples and leiomyomas examined by Pan et al. \[[@CR10]\] and Wang et al. \[[@CR12]\] make these molecules putative markers distinguishing uterine sarcomas and mixed epithelial--mesenchymal tumors from leiomyomas. All these miRs were up-regulated in leiomyomas and commonly down-regulated in the tumors analyzed in our study. miR-21 is a proapoptotic oncomir \[[@CR20]\], regulating multiple programs that enhance cell proliferation, apoptosis, and tumor invasiveness by targeting, e.g., PTEN, PDCD4, and RECK \[[@CR21]\]. Its increased expression has been observed in many tumors, including endometrial cancer \[[@CR22]\] and cervical cancer \[[@CR23]\]. Our findings on *miR-21* are similar to those in eutopic endometrium of women with endometriosis by Pan et al. \[[@CR15]\] who demonstrated a slight down-regulation of *miR-21* in these tissues compared to normal endometrium. miR-23b also functions as an oncomir, by targeting proline oxidase (POX), which suppresses proliferation and induces apoptosis through generation of reactive oxygen species \[[@CR24]\] and by inhibiting invasion via suppressing several prometastatic genes \[[@CR25]\]. An oncomir activity of miR-27a has also been observed. It down-regulates prohibitin (PHB, anti-proliferative protein), as documented in gastric adenocarcinoma cells \[[@CR26]\], and targets Sprouty2 (Spry2, tumor supressor, an antagonist of the Ras/MAPK signaling pathway) in pancreatic adenocarcinoma cells \[[@CR27]\]. In view of the above, our results on the three oncomirs, *miR-21*, *miR-23b*, and *miR-27a*, to be under-expressed in tumor samples may suggest that their oncogenic role is relative. Yet our findings on a common decrease in the expression of the *let-7* family members (*let-7a*, *let-7b*, *let-7c*, *let-7d*, *let-7e*, *let-7f*, *let-7g* and *let-7i*) in tumor samples support the notion of let-7 family members as tumor suppressors influencing survival \[[@CR28] and references therein\]. Most or all *let-7* family members are down-regulated in many cancer types, including sarcomas \[[@CR29]\].

Additional putative markers distinguishing uterine sarcomas and mixed epithelial--mesenchymal tumors from leiomyomas are *miR-32* and *miR-144* molecules. According to Pan et al. \[[@CR10]\] both miRs are down-regulated in leiomyomas. *MiR-32* was commonly up-regulated in all the tumors analyzed in our study while the expression of *miR-144* remained unchanged when compared to the control samples. miR-32 may have an anti-apoptotic activity, as in human leukemia 60 (HL60) cells it was shown to reduce the expression of *BCL2L11* encoding the proapoptotic protein Bim \[[@CR30]\]. miR-144 (functioning in a cluster with miR-451) promotes erythropoiesis \[[@CR31]\], down-regulates insulin receptor substrate 1 (IRS1) \[[@CR32]\] and represses NRF2 \[[@CR33]\], a key regulator of oxidative stress response in erythrocytes. miR-144 confers protection against simulated ischemia/reperfusion-induced cardiomyocyte death via targeting CUG triplet repeat-binding protein 2 (CUGBP2)--COX-2 pathway \[[@CR34]\].

This preliminary study also provides hints for the future investigations on the altered miRs that have not reached the statistical significance in our small series of samples. The fold change values of the average expression of all the analyzed miRs between tumor and control samples are provided in ESM Supplementary Table [1](#MOESM1){ref-type="media"}. In addition, our results on miR expression in the uterine sarcoma cell lines, SK-UT-1 and ME-SA, presented in ESM Supplementary Fig. [1](#MOESM2){ref-type="media"}, demonstrate a marked discrepancy between the profiles of cell lines and the matched clinical material and prove that cell lines are inadequate controls for miRNA studies in uterine sarcomas.

To conclude, we identified miRNAs, which are deregulated in uterine sarcomas and mixed epithelial--mesenchymal uterine tumors. While we recognize the low number of tissues profiled by a histopathological subtype as a limitation of our study, this is the first report on differential miRNA signatures across the subtypes of uterine sarcomas. By identifying significant differences in miRs' expression levels in tumors compared to normal uterine tissues (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"})---though, perhaps due to the small series of samples, no specific miRNA subset classifying these subtypes was distinguished---our findings provide insights into the biology of these tumors. Some of these molecules, when further validated, may prove to have a value of biomarkers for uterine lesions. Profiling miR expression in uterine sarcomas and mixed uterine tumors and other uterine entities may provide a valuable tool for the differential diagnosis between uterine tumor subtypes and between malignant and benign uterine pathologies.
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